Compositions for a dietary supplement to manage senescent cells
US-2024390346-A1 · Nov 28, 2024 · US
Sglt1/2 inhibitor lik066 for treating obesity
US2020121639A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2020121639-A1 |
| Application number | US-201816490554-A |
| Country | US |
| Kind code | A1 |
| Filing date | Mar 2, 2018 |
| Priority date | Mar 3, 2017 |
| Publication date | Apr 23, 2020 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is drawn to methods for effecting weight loss, e.g.. in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se.
First claim
Opening claim text (preview).
1 . A method of treating obesity comprising administering to a patient in need, a dosage of 1.0-200.0 mg of LIK066, or salt thereof. 2 . The method according to claim 1 , wherein the dosage is selected from the group consisting of 2.5 mg, 5.0 mg, 10.0 mg, 25.0 mg, 35 mg, and 50 mg. 3 . The method according to claim 1 , wherein the dosage is administered once a day. 4 . The method according to claim 1 , wherein the dosage is administered twice a day. 5 . The method according to claim 1 , wherein the administered dosage ameliorates the side effects of diarrhea. 6 . A method for effecting weight loss in a patient having a body mass index of at least 25 kg/m 2 , comprising administering an escalating unit dosage form comprising administering to a patient in need, a dosage of 1.0-200.0 mg of LIK066, or salt thereof. 7 . The method of claim 6 , wherein the subject has a body mass index between 25 kg/m 2 and 29.9 kg/m 2 . 8 . The method of claim 6 , wherein the subject has a body mass index of at least 30 kg/m 2 . 9 . The method of claim 1 , wherein the escalating unit dosage form is formulated for oral administration. 10 . The method of claim 1 , wherein the weight loss is effective to achieve a reduction of at least about 10% of body weight. 11 . The method according to claim 1 , wherein the dosage is administered once a day. 12 . The method according to claim 1 , wherein the dosage is administered twice a day. 13 . The method according to claim 1 , wherein the administered dosage ameliorates the side effects of diarrhea.
Assignees
Inventors
Classifications
- A61K31/357Primary
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title
Anorexiants; Antiobesity agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2020121639A1 cover?
- The present invention is drawn to methods for effecting weight loss, e.g.. in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se.
- Who is the assignee on this patent?
- Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K31/357. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Apr 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).